Edick Paul R 4
4 · Xeris Biopharma Holdings, Inc. · Filed Jan 31, 2024
Insider Transaction Report
Form 4
Edick Paul R
DirectorSee Remarks
Transactions
- Award
Common Stock
2024-01-31+1,500,000→ 3,788,064 total - Award
Stock Appreciation Right
2024-01-31+500,000→ 500,000 totalExercise: $2.46Exp: 2026-03-03→ Common Stock (500,000 underlying)
Holdings
- 33,430(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
- [F2]The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F3]The award will vest in full on the two-year anniversary of the grant date.
- [F4]Upon exercise, the Stock Appreciation Right will be settled in cash.